peposertib

Drug Overview

Peposertib is an investigational oral medication being studied for its ability to treat various forms of advanced cancer. It belongs to a modern class of medicines known as Targeted Therapy. Unlike standard chemotherapy, which kills all fast-growing cells, peposertib is designed to be a “Smart Drug” that interferes with the specific way cancer cells fix their own DNA. By blocking these repairs, it makes cancer cells more vulnerable to other treatments like radiation or chemotherapy.

• Generic Name: Peposertib (also known as M3814)
• US Brand Names: None (Currently an experimental agent)
• Drug Class: DNA-Dependent Protein Kinase (DNA-PK) Inhibitor; Targeted Therapy
• Route of Administration: Oral (Tablet taken by mouth)
• FDA Approval Status: Not FDA Approved (Currently in Phase 1 and Phase 2 clinical trials)
  
  Read about peposertib and its role in DNA repair inhibition. Trust our medical experts to design the best personalized cancer care plan for you.

What Is It and How Does It Work? (Mechanism of Action)

To understand how peposertib works, you first have to understand how cancer survives. Treatments like radiation and certain chemotherapies work by breaking the DNA inside cancer cells. Normally, a cell has “repair crews” that fix these breaks so the cell can keep living.

Peposertib works at the molecular level by targeting one of the most important repair crews, an enzyme called DNA-Dependent Protein Kinase (DNA-PK).

• The Signaling Pathway: When radiation causes a “double-strand break” (a complete snap in the DNA ladder), the DNA-PK enzyme rushes to the site of the damage. It acts as a bridge to hold the broken ends together and sends signals to other proteins to come and “glue” the DNA back together.
• The Blockade: Peposertib is a small molecule that enters the cancer cell and plugs into the DNA-PK enzyme. This effectively “handcuffs” the repair crew.
• Cell Death: Because the DNA cannot be repaired, the cancer cell becomes overwhelmed by its own broken genetic code. It can no longer divide and eventually undergoes a process of self-destruction called apoptosis.
• The “Sensitizer” Effect: Because peposertib stops repairs, it makes standard treatments much more powerful. This allows doctors to potentially use lower doses of radiation while still getting better results.

FDA-Approved Clinical Indications

As of 2026, peposertib has not yet received full FDA approval for general use. It is strictly available through clinical research studies.

Oncological Uses (Investigational):

• Rectal Cancer: Studied in combination with chemoradiation.
• Advanced Solid Tumors: Used in combination with other DNA-damaging drugs.
• Head and Neck Squamous Cell Carcinoma: Researching its effect when paired with radiation therapy.
• Soft Tissue Sarcoma: Investigating its use in difficult-to-treat tissue cancers.

Non-oncological Uses:

• None.

Dosage and Administration Protocols

In clinical trials, peposertib is taken daily as an oral tablet. The exact dose often depends on the other treatments (like radiation) the patient is receiving at the same time.

• 
  Dose Adjustments: Physicians monitor liver function closely. If liver enzymes (ALT/AST) rise significantly, the dose may be reduced or paused. Specific adjustments for kidney (renal) insufficiency are currently being determined in ongoing studies.

Clinical Efficacy and Research Results

Clinical data from 2020 to 2025 has focused on how well peposertib “boosts” standard cancer care.

• Rectal Cancer Studies: In Phase 1b trials, researchers found that adding peposertib to standard chemoradiation resulted in a high rate of “Pathologic Complete Response.” This means that in a significant number of patients, no visible cancer was left at the time of surgery.
• Numerical Data: Early research indicated that the combination was safe and achieved a disease control rate in over 70% of participants in specific trial cohorts.
• Survival Trends: While long-term 5-year survival rates are still being calculated, early data suggests that the “Progression-Free Survival” (the time a patient lives without the cancer growing) is improved when peposertib is added to certain chemotherapy regimens compared to chemotherapy alone.

Safety Profile and Side Effects

Because peposertib is usually given with radiation or chemotherapy, it can increase the side effects of those treatments.

Black Box Warning:

• There is no official Black Box Warning as the drug is not yet approved.

Common Side Effects (>10%)

• Nausea and Vomiting: Upset stomach is common but usually manageable.
• Fatigue: Feeling unusually tired or weak.
• Skin Redness: Especially in the area receiving radiation (Radiation Dermatitis).
• Diarrhea: Common when treating cancers in the abdominal or rectal area.
• Low Blood Counts: A drop in white blood cells (Neutropenia).

Serious Adverse Events

• Hepatotoxicity: Temporary but significant stress on the liver.
• Severe Skin Reactions: Intense peeling or blistering in radiation zones.
• Bone Marrow Suppression: Dangerously low blood counts that may lead to infection.

Management Strategies

• For Nausea: Anti-nausea medications are often prescribed to be taken before the peposertib tablet.
• For Skin: Special medical-grade creams and avoiding sun exposure on the radiation site are recommended.

Research Areas

In the fields of Immunotherapy and regenerative medicine, peposertib is a drug of high interest. Researchers are currently exploring “Immunogenic Cell Death.” When peposertib stops DNA repair and the cancer cell bursts, it releases “flags” that help the body’s immune system recognize the cancer. Ongoing research is testing if peposertib can be used alongside “Checkpoint Inhibitors” to help the immune system regenerate a more powerful defense against tumors that were previously “invisible” to the body’s natural soldiers.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Liver Function Panel: To ensure the liver can process the medication.
• Complete Blood Count (CBC): To establish baseline blood health.
• Imaging (CT/MRI): To measure the tumor size before starting the “sensitizer” therapy.

Precautions During Treatment

• Sun Sensitivity: This medication can make your skin more sensitive to light. Wear protective clothing and high-SPF sunscreen.
• Pregnancy: Peposertib can harm a developing fetus. Highly effective birth control is required for both men and women during treatment.

“Do’s and Don’ts” List

• DO take your dose exactly as timed by your radiation oncologist—timing is critical for the drug to work with the radiation.
• DO report any yellowing of the eyes or skin (jaundice) immediately.
• DON’T take any new herbal supplements (like St. John’s Wort) without asking your doctor, as they can interfere with the drug.
• DON’T skip blood test appointments; these are vital to ensure your liver and bone marrow stay healthy.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Peposertib is an investigational drug and is not available for use outside of clinical trials. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or participation in clinical research.